Mafenide adverse reactions: Difference between revisions
(Created page with "__NOTOC__ {{Mafenide}} {{CMG}}; {{AE}} {{chetan}} ==Adverse Reactions== In the clinical setting of severe burns, it is often difficult to distinguish between an adverse reac...") |
|||
| Line 5: | Line 5: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
In the clinical setting of severe burns, it is often difficult to distinguish between an adverse reaction to Mafenide Acetate and burn sequelae. In a clinical study of pediatric patients with acute burns requiring autografts who received Mafenide Acetate,USP for 5% SOLUTION in addition to double antibiotic solution (DAB) wound therapy (neomycin sulfate 40 mg and polymyxin B 200,000 units/ liter), the incidence of rash (4.6%) and itching (2.8%) in the group which received Mafenide Acetate USP For 5% Solution was not different from that experienced with (DAB) dressings alone (5.7% and 1.3%, respectively). | In the clinical setting of severe burns, it is often difficult to distinguish between an adverse reaction to Mafenide Acetate and burn sequelae. In a clinical study of pediatric patients with acute burns requiring autografts who received Mafenide Acetate,USP for 5% SOLUTION in addition to double antibiotic solution (DAB) wound therapy ([[neomycin sulfate]] 40 mg and [[polymyxin B]] 200,000 units/ liter), the incidence of rash (4.6%) and itching (2.8%) in the group which received Mafenide Acetate USP For 5% Solution was not different from that experienced with (DAB) dressings alone (5.7% and 1.3%, respectively). | ||
From other clinical settings, a single case of bone marrow depression and a single case of an acute attack of [[porphyria]] have been reported following therapy with Mafenide Acetate. Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a [[glucose-6-phosphate dehydrogenase deficiency]], has been reported following therapy with mafenide acetate. The following adverse reactions have been reported with topical Mafenide Acetate therapy:<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAFENIDE ACETATE POWDER, FOR SOLUTION [PAR PHARMACEUTICAL COMPANIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e48cc935-2058-48c0-9281-b8b919629493 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 05:08, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Adverse Reactions
In the clinical setting of severe burns, it is often difficult to distinguish between an adverse reaction to Mafenide Acetate and burn sequelae. In a clinical study of pediatric patients with acute burns requiring autografts who received Mafenide Acetate,USP for 5% SOLUTION in addition to double antibiotic solution (DAB) wound therapy (neomycin sulfate 40 mg and polymyxin B 200,000 units/ liter), the incidence of rash (4.6%) and itching (2.8%) in the group which received Mafenide Acetate USP For 5% Solution was not different from that experienced with (DAB) dressings alone (5.7% and 1.3%, respectively).
From other clinical settings, a single case of bone marrow depression and a single case of an acute attack of porphyria have been reported following therapy with Mafenide Acetate. Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenide acetate. The following adverse reactions have been reported with topical Mafenide Acetate therapy:[1]
References
Adapted from the FDA Package Insert.